73515-08-9

Usage

Uses

Used in Chemical Synthesis:
1-(4-iodobutyl)-4-methoxybenzene is used as a building block for the preparation of various pharmaceuticals and organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of complex organic molecules.
Used in Organic Electronic Devices:
1-(4-iodobutyl)-4-methoxybenzene has been studied for its potential use in organic electronic devices due to its electronic properties. Its incorporation into device structures can enhance performance and contribute to the development of advanced electronic technologies.
Used in Medicinal Chemistry Research:
1-(4-iodobutyl)-4-methoxybenzene is also a target for medicinal chemistry research. Its unique structure and reactivity make it a promising candidate for the development of new drugs and therapeutic agents, with potential applications in various medical fields.

Upstream product

• 52244-70-9 4-(4-methoxyphenyl)butan-1-ol 
• 35191-43-6 1-(4-bromo-butyl)-4-methoxy-benzene 
• 288-32-4 1H-imidazole 

Downstream Products

• 134304-39-5 1-Methoxy-4-(4-nitro-butyl)-benzene 
• 153748-36-8 3-[4-(4-Methoxyphenyl)butyloxy]-6-methyl-2-pyridine carboxaldehyde 
• 864156-80-9 [6-(4-methoxy-phenyl)-hex-1-ynyl]-trimethyl-silane 
• 108185-82-6 4-(4-Nitro-butyl)-phenol 
• 1027977-09-8 3-{6-(2-Methoxycarbonyl-ethyl)-5-[4-(4-methoxy-phenyl)-butoxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid methyl ester 
• 1026812-51-0 3-{6-((E)-2-Methoxycarbonyl-vinyl)-5-[4-(4-methoxy-phenyl)-butoxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid methyl ester 
• 1025972-13-7 3-{6-Hydroxymethyl-3-[4-(4-methoxy-phenyl)-butoxy]-pyridin-2-yl}-propionic acid methyl ester 
• 170569-18-3 (E)-3-{3-[4-(4-Methoxy-phenyl)-butoxy]-6-methyl-1-oxy-pyridin-2-yl}-acrylic acid methyl ester 
• 170569-19-4 (E)-3-{6-Hydroxymethyl-3-[4-(4-methoxy-phenyl)-butoxy]-pyridin-2-yl}-acrylic acid methyl ester 
• 170569-17-2 (E)-3-{3-[4-(4-Methoxy-phenyl)-butoxy]-6-methyl-pyridin-2-yl}-acrylic acid methyl ester 

Relevant academic research and scientific papers

Fluorination Triggers Fluoroalkylation: Nucleophilic Perfluoro-tert-butylation with 1,1-Dibromo-2,2-bis(trifluoromethyl)ethylene (DBBF) and CsF

Perfluoro-tert-butylation reaction has long remained a challenging task. We now report the use of 1,1-dibromo-2,2-bis(trifluoromethyl)ethylene (DBBF) as a practical reagent for perfluoro-tert-butylation reactions for the first time. Through a consecutive triple-fluorination process with DBBF and CsF, the (CF3)3C? species can be liberated and observed, which is able to serve as a robust nucleophilic perfluoro-tert-butylating agent for various electrophiles. The power of this synthetic protocol is evidenced by the efficient synthesis of structurally diverse perfluoro-tert-butylated molecules. Multiple applications demonstrate the practicability of this method, as well as the superiority of perfluoro-tert-butylated compounds as sensitive probes. The perfluoro-tert-butylated product was successfully applied in 1H- and 19F-magnetic resonance imaging (MRI) experiment with an ultra-low field (ULF) MRI system.

Electrophilic Iron Catalyst Paired with a Lithium Cation Enables Selective Functionalization of Non-Activated Aliphatic C?H Bonds via Metallocarbene Intermediates

Combining an electrophilic iron complex [Fe(Fpda)(THF)]2 (3) [Fpda=N,N′-bis(pentafluorophenyl)-o-phenylenediamide] with the pre-activation of α-alkyl-substituted α-diazoesters reagents by LiAl(ORF)4 [ORF=(OC(CF3)3] provides unprecedented access to selective iron-catalyzed intramolecular functionalization of strong alkyl C(sp3)?H bonds. Reactions occur at 25 °C via α-alkyl-metallocarbene intermediates, and with activity/selectivity levels similar to those of rhodium carboxylate catalysts. Mechanistic investigations reveal a crucial role of the lithium cation in the rate-determining formation of the electrophilic iron-carbene intermediate, which then proceeds by concerted insertion into the C?H bond.

Azole derivatives

Compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, are disclosed. Also disclosed are methods of preparation of the above-mentioned compounds, pharmaceutical compositions and salts and esters

Novel pentafluorosulfanyl compounds

The present invention provides the compounds of formula I-A their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing th

Novel oxidized thioether derivatives

The present invention provides the compounds of formula I their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them

Pharmaceutical pyridine compounds

This invention relates to a compound of formula I STR1 These compounds are leukotriene antagonists and as such can be used in treating various diseases associated with leukotrienes.

PHARMACEUTICAL PYRIDINE COMPOUNDS

This invention relates to a compound of formula 1 STR1 or an N-oxide, or a pharmaceutically acceptable salt, where A is CH 2 and Z is S(O). sub.q where q is 0, 1 or 2, CH 2, CHOH, CO, NR x, or O, orA is C=O and Z is NR x ;m is 0-5;R x

(E)-3-[[[[6-(2-Carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2- pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: High affinity leukotriene B4 receptor antagonists

(E)-3-[[[[6-(2-Carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl]oxy]-2- pyridinyl]-methyl]thio]methyl]benzoic acid (11, SB 201993) is a novel, potent LTB4 receptor antagonist. Compound 11 arose from a structure-activity study of a series of trisubstituted pyridines that demonstrated LTB4 receptor antagonist activity. The placement of an additional methylene unit in the sulfur containing chain linking the pyridine and benzoic acid moieties of lead compound 8 (K(i) = 80 nM) resulted in a greater than 10-fold increase in receptor affinity. Additionally, in this new series of compounds, the oxidation state of the sulfur was found to be critical to the activity, i.e., the sulfoxide and sulfone showed substantially lower affinity for the LTB4 receptor. Compound 11 competitively inhibits the binding of [3H]LTB4 to LTB4 receptors on human polymorphonuclear leukocutes with a K(i) of 7.1 nM and blocks both the LTB4-induced calcium mobilization and the LTB4-induced degranulation responses in these cells with IC50 values of 131 and 271 nM, respectively. Compound 11 demonstrated oral LTB4 antagonist activity as well as topical antiinflammatory activity in the mouse.

INTRAMOLECULAR RADICAL CYCLIZATION OF PHENOLIC NITRONATES: FACILE SYNTHESIS OF ANNELATED TROPONE AND TROPOLONE DERIVATIVES

Treatment of the phenolic nitroalkanes 1 in dilute base with K3Fe(CN)6 results in the formation of spirocyclic nitro dienones 3 which undergo facile rearrangement to annelated tropone or tropolone derivatives.